Sector: Pharmaceutical Preparations · Industry: Biotechnology · Exchange: Nasdaq
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, MA · Employees: 48 · Website: https://www.camp4tx.com
Camp4 Therapeutics Corp (CAMP) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Competitors of Camp4 Therapeutics Corp (CAMP) tracked by Macroplane include NVIDIA CORP (NVDA), Alphabet Inc. (GOOGL), Apple Inc. (AAPL), MICROSOFT CORP (MSFT), Broadcom Inc. (AVGO), Taiwan Semiconductor Manufacturing Co. (TSMC) (2330.TW), Meta Platforms, Inc. (META), Samsung Electronics Co., Ltd. (005930.KS), and 4 more.
Search companies · Macro trends · Industries · Product categories · Baskets